BioCryst Pharmaceuticals develops oral medicines for rare and serious diseases, with a flagship commercial product for hereditary angioedema (HAE). Its pipeline and marketed therapies emphasize small-molecule approaches that patients can take at home rather than injectable biologics alone. The company serves specialist physicians and patients in rare-disease markets where few oral alternatives have historically existed.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 145.5 | — | 0 | — |
| Q2 2025 | 163.3 | — | 5.1 | — |
| Q3 2025 | 159.4 | — | 12.9 | — |
| Q4 2025 | 406.6 | — | 245.8 | — |
| Q1 2026 | 156.4 | 7.5% | -721.8 | -2,255,762.5% |
| Q2 2026 | 218.3 | 33.6% | 78.4 | 1,441.7% |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: City Holding Company (CHCO), Porch Group, Inc. (PRCH), Aehr Test Systems, Inc. (AEHR), Werner Enterprises, Inc. (WERN), Driven Brands Holdings Inc. (DRVN), Marqeta, Inc. (MQ)